OTLK - OTLK STOCK ALERT: Robbins LLP Reminds Investors of January 2 2024 Lead Plaintiff Deadline in the Class Action Filed Against Outlook Therapeutics Inc. | Benzinga
SAN DIEGO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ:OTLK) securities between December 29, 2022 and August 29, 2023. Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The Company's lead product candidate is ONS-5010, an ophthalmic formulation of the antibody bevacizumab for the treatment of wet age-related macular degeneration ("wet AMD") and other retina diseases.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: Outlook Therapeutics, Inc. (OTLK) Misled Investors About the Viability and Efficacy of its Lead Product Candidate
According to the complaint, during the class period, defendants failed to disclose that: (i) there was a lack of substantial evidence supporting ONS-5010 as a treatment for wet AMD; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls ("CMC") and other ...